The Rising Influence of Rising Affluence

[DewDiligence]

Bayer won’t pull glyphostate from the market or admit to a safety issue, which would only magnify the potential liability. Instead, Bayer will try to introduce a successor compound in the next couple of years that works on glyphostate-resistant weeds, and they’ll make resistance (not safety) the marketing angle for the new product.

It’s a tough task from a technical and regulatory standpoint, but Bayer has no other option that makes sense economically.